- Unique test facility comprising a bioreactor and electrolyzer under construction in Marl (Germany).
- High-value specialty chemicals produced from CO2 and water using electricity from renewable sources and bacteria.
- Rheticus II will receive funding of around €3.5 million from Germany's Federal Ministry of Education and Research (BMBF).
Essen. Evonik and Siemens today launched their joint research project Rheticus II. The goal is to develop an efficient and powerful test plant that will use carbon dioxide (CO2) and water as well as electricity from renewable sources and bacteria to produce specialty chemicals. In the Rheticus I project, the two companies worked for two years to develop the technically feasible basis for artificial photosynthesis using a bioreactor and electrolyzers. Evonik and Siemens are now combining these two, previously separate, plants in a test facility at Evonik’s site in Marl (Germany). Rheticus II will run until 2021 and will receive funding of around €3.5 million from Germany’s Federal Ministry of Education and Research (BMBF).
“The innovative technology used for Rheticus has the potential to contribute to the success of Germany's energy transition,” says Thomas Haas, who is responsible for the Rheticus project at Evonik. “In the future, this platform could be installed anywhere CO2 is available—for example, at power plants or biogas plants. We use available CO2 as the raw material for the production of high-value chemicals using artificial photosynthesis.” Siemens is contributing the world's first CO2 electrolyzer to the Rheticus project. “We are developing a flexible system that can provide answers to various questions raised by the energy transition,” says Karl-Josef Kuhn, who is in charge of Power2X research at Siemens. “We are making it possible to store renewable energy by converting it into useful substances such as specialty chemicals or fuel. We are also contributing to the stability of the grid because production is so flexible that we can respond to fluctuations in power supply.”
The test facility is scheduled to start operating in early 2020. It comprises electrolyzers and a bioreactor. In a first step, carbon dioxide and water are converted into carbon monoxide (CO) and hydrogen in electrolyzers with the aid of electricity. Special microorganisms then convert the CO in the gases synthesized in this way into chemicals. Siemens and Evonik are each contributing their core competencies—electrolysis and biotechnology—to this artificial photosynthesis process. Artificial photosynthesis means combining chemical and biological steps so that energy can be used to produce viable chemicals from CO2 and water. Plants use natural photosynthesis in a similar way: chlorophyll, enzymes and sunlight are used to synthesize glucose—a vital, energy-rich nutrient. An other advantage of Rheticus is, that the technology platform also contributes to the reduction of carbon dioxide levels in the atmosphere, as it uses CO2 as a raw material. Three tons of carbon dioxide would be needed to produce one tonne of butanol, for example.
The synthesis module came on stream at Evonik in spring 2019. At its heart is an 8-meter high stainless steel bioreactor with capacity of 2,000 liters. Microorganisms work continuously in the reactor. Their main nutrients are hydrogen and carbon monoxide. Siemens has developed a fully automated CO2 electrolyzer which was integrated into a container in summer 2019. The world's first CO2 electrolyzer comprises 10 cells and the total surface area of the electrodes is 3,000 cm2.
The electrolyzer and the bioreactor will be combined in the coming months. In addition, a unit to process the liquid from the bioreactor is being built to obtain pure chemicals.
In the test facility, bacteria will produce butanol and hexanol for research purposes. These substances are used as starting products, for example, for specialty plastics and food supplements. However other specialty chemicals are conceivable, depending on the bacterial strain and conditions.
Following successful completion of Rheticus II, Evonik and Siemens will have a unique technology platform allowing production of useful, energy-rich substances such as specialty chemicals and artificial fuels from CO2 in a flexible, modular process.
Image 1: In Evonik's module for the Rheticus test facility, bacteria convert synthesis gases into specialty chemicals such as butanol. Source: Evonik
Image 2: The world’s first fully automated CO2 electrolyzer from Siemens generates carbon monoxide. Together with hydrogen, it delivers the main nutrients for the bacteria in the bioreactor. Source: Siemens
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 170 years. The company is active around the globe, focusing on the areas of electrification, automation and digitalization. One of the largest producers of energy-efficient, resource-saving technologies, Siemens is a leading supplier of efficient power generation and power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. With its publicly listed subsidiary Siemens Healthineers AG, the company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2018, which ended on September 30, 2018, Siemens generated revenue of €83.0 billion and net income of €6.1 billion. At the end of September 2018, the company had around 379,000 employees worldwide. Further information is available on the Internet at www.siemens.com.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.